XERS (Xeris Biopharma Holdings) Tariff Resilience Score: 7/10 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XERS Xeris Biopharma Holdings Inc XERS
71 GF Score
Price $8.80
GF Value $5.22
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Xeris Biopharma Holdings Tariff Resilience Score?

Xeris Biopharma Holdings XERS +1.15% 71 Tariff Resilience Score is 7 as of Jul. 18, 2026. GuruFocus rates XERS with a GF Score™ of 71/100 and a GF Value™ of $5.22 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Xeris Biopharma Holdings ranks better than 97.08% on this metric.

Xeris Biopharma Holdings has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Xeris Biopharma Holdings has Xeris Biopharma's focus on pharmaceuticals with a strong domestic market presence reduces tariff exposure. While some raw materials may be imported, its overall impact is limited.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Xeris Biopharma Holdings might have Highly Resilient.

Xeris Biopharma Holdings  (NAS:XERS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Xeris Biopharma Holdings Tariff Resilience Score Related Terms

XERS vs PAHC, PRGO, ALVO: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Xeris Biopharma Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xeris Biopharma Holdings Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Xeris Biopharma Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Xeris Biopharma Holdings's Tariff Resilience Score falls into.


XERS
71GF Score
Xeris Biopharma Holdings Inc XERS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Xeris Biopharma Holdings (XERS) has a Tariff Resilience Score of 7 as of Jul. 18, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Xeris Biopharma Holdings ranks #30 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Xeris Biopharma Holdings' Tariff Resilience Score too high?
Xeris Biopharma Holdings' current Tariff Resilience Score is 7. Based on the distribution chart, Xeris Biopharma Holdings ranks #30 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Tariff Resilience Score compare to PAHC and PRGO?
According to the Drug Manufacturers industry distribution chart, Xeris Biopharma Holdings ranks #30 out of 1029 companies for Tariff Resilience Score. This places Xeris Biopharma Holdings in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Xeris Biopharma Holdings's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (XERS) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.22, compared to a current price of $8.80 — trading 68.6% above its estimated fair value. The current Tariff Resilience Score is 7. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Xeris Biopharma Holdings (XERS), the current Tariff Resilience Score is 7 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xeris Biopharma Holdings (XERS) Overvalued in 2026?

Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued. The current stock price of $8.80 is trading 68.6% above its estimated GF Value™ of $5.22. GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.

Key valuation signals for XERS:

  • Tariff Resilience Score: 7
  • GF Value™: $5.22 vs. price of $8.80 (68.6% above fair value)
  • GF Score™: 71/100 with 7 warning signs

No single metric tells the full story. See the XERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xeris Biopharma Holdings Business Description

Other Exchanges 0A8E:UK2B30:Germany
Address 1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score

Get the complete analysis for XERS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.80
Price
$5.22
GF Value